![]() ![]() ![]() “We are thrilled to be the first company to integrate Emerald Innovations’ technology into an ALS study. Analyses of the Emerald data will be used to assess changes in patients being treated with increasing doses of VRG50635. Through the collaboration, Emerald’s wireless digital health sensors will be placed in study participants’ homes to continuously measure key neurological functions affected by ALS, including sleeping, breathing, walking, and mobility. ![]() SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE)-Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced that Emerald Innovations’ wireless digital health technology will be used to capture critical patient data in its planned Phase 1b proof-of-concept study of the PIKfyve inhibitor VRG50635, a novel therapeutic in clinical development for amyotrophic lateral sclerosis (ALS). ![]()
0 Comments
Leave a Reply. |